Cambridge Healthtech Institute’s Inaugural

Drug Discovery in Women’s Health

April 14, 2025

Women’s health has been a challenging area for drug discovery and development and that’s evident from the low number of new drug launches in this area, in recent years. Is it the lack of scientific knowledge, technical resources, funding, clinical trial limitations, social inhibitions, or all the above? Our new symposium on Drug Discovery in Women’s Health brings together key stakeholders to discuss what is needed—on both the scientific and the technological fronts—to close the gap and bring forth promising therapeutic options to advance women’s healthcare. It provides a perfect backdrop for the conferences that follow, which focus on novel drug discovery approaches like degraders and molecular glues and the use of technologies like AI and machine learning that can be applied to a variety of therapeutic areas.

Coverage will likely include:

Overview on opportunities and challenges facing drug discovery for women’s health
Updates on progress being made in gynecological cancers, endometriosis, PCOS, osteoporosis, oral IVF
Development in emerging tools and drug modalities that can be leveraged for women’s health
Translational and clinical challenges in drug development
Key government initiatives and current gaps in knowledge and resources
Perspectives from venture capital firms focused on women’s health

The deadline for priority consideration is September 27, 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: